trending Market Intelligence /marketintelligence/en/news-insights/trending/yZU-VmBz4p6TGCQHloaRxg2 content esgSubNav
In This List

Exelixis gets FDA priority review to expand use of kidney cancer drug

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond


Exelixis gets FDA priority review to expand use of kidney cancer drug

The U.S. Food and Drug Administration granted priority review to Exelixis Inc.'s supplemental new drug application for Cabometyx to treat patients with previously untreated advanced renal cell carcinoma.

The application is based on data from a phase 2 trial. The FDA will take a decision on the drug by Feb. 15, 2018.

On April 25, 2016, Cabometyx was approved by the agency to treat advanced renal cell carcinoma in patients who have received prior anti-angiogenic therapy.